Light microscopy autoradiography has been used to visualize neuroanatomical patterns of brain opiate receptor upregulation in response to chronic naltrexone administration. Slide-mounted brain sections of frozen rat brain were labeled in vitro with dihydro[3H]morphine, a relatively selective ,u opioid ligand. The greatest relative increases in opiate receptor density were observed in the nucleus accumbens, the amygdala, striatal patches, nuclei of the thalamus and hypothalamus, layers I and III of neocortex, substantia nigra compacta, midbrain periaqueductal gray regions, and the parabrachial nuclei of the brainstem. The substantia nigra reticulata, surrounding areas of striatal patches, and the locus ceruleus, were not affected by this drug treatment. These findings demonstrate that chronically administered naltrexone differentially regulates opiate receptors throughout the brain. In particular, three brain systems appear to be target areas of receptor upregulation: (i) the dopamine A9/AlO systems, (ii) the limbic system, and (iii) structures that receive input from afferent sensory pathways. Two possible mechanisms to account for this finding are (i) that the drug does not have uniform effects throughout the brain or (it) that the receptors themselves may be associated with different functional systems. Receptor density changes are paralleled by increases in methionine-enkephalin content in the striatum, nucleus accumbens, periaqueductal gray, and hypothalamic areas of chronic naltrexone-treated rats relative to control rats. Thus opiate receptors and opioid peptides appear to be subject to regulatory mechanisms similar to those that modulate other neurotransmitters and their receptors. These results document in a visual manner brain patterns of opiate receptor upregulation.
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Opiate narcotic analgesics produce tolerance and dependence in vivo and desensitization in vitro. The observation of these phenomena has raised the question as to whether opiate receptors undergo up-or downregulation in vivo, in response to long-term administration of opiate drugs. Opiate receptor downregulation has been difficult to document. Several groups have reported that chronic administration of narcotic agonists in vivo does not produce any change in either receptor number or affinity (1) (2) (3) (4) (5) (6) (7) . On the other hand, receptor downregulation has been observed in neurotumor cell lines after long-term exposure to enkephalin (8-10) but not to alkaloid agonists (8) . Possible interpretations of the latter findings are (i) that opioid peptides bind differently than do opioid narcotic agonists to the same receptor or (ii) that only a subpopulation of opioid receptors can be so modulated.
By contrast, upregulation of brain opiate receptors in vivo after drug-induced denervation (11) or long-term narcotic antagonist administration (12) is well established (7, 13, 14) . Chronic blockade of opiate receptors results in a nearly 2-fold increase in the density of both ,u and 8 receptors (12) . The newly synthesized or unmasked receptors are more sensitive to guanyl nucleotide modulation, a finding which suggests that receptor upregulation may be accompanied by an increased coupling to the guanyl nucleotide regulatory protein (Ni). That brain opiate receptors undergo upregulation is of interest for several reasons. First, in animal behavioral studies, long-term administration of antagonist leads to a supersensitivity to morphine in analgesia paradigms (13, 15) . Second, guinea pig ilea exposed to naloxone for 1-2 weeks in vivo show an enhanced sensitivity to the inhibitory properties of morphine in the twitch assay (14) . Third, there are potential clinical ramifications of naltrexone-induced opiate receptor supersensitivity both for naltrexone treatment of heroin addicts and as a possible aid in pain therapy to enhance the analgesic effects of morphine.
The present investigation was carried out to identify those structures of the central nervous system that undergo opiate receptor density changes in response to chronic antagonist exposure. Using quantitative autoradiography, we have identified specific functional pathways involved in the upregulation process. In this sense, autoradiography has been used to reveal a dynamic picture of receptor density changes after a particular drug regimen and thereby documents in a visual manner an example of neuronal plasticity.
MATERIALS AND METHODS
Male Sprague-Dawley rats (150-200 g) were used for all experiments. Brains were analyzed from animals treated with (i) chronic naltrexone, (ii) acute naltrexone, and (iii) no drug (for controls). For chronic naltrexone animals, antagonist was delivered via an osmotic minipump. One model 2001 Alzet minipump (Alza) was inserted subcutaneously in the dorsal subcapsular space of each rat; incisions were closed with sutures. Pumps were filled with naltrexone HCl (70 mg/ml; National Institute on Drug Abuse) 8 days before sacrifice. Contents of the pump reservoir were delivered at a constant rate of 1 ,ul/hr for 7-8 days. In the case of acute naltrexone treatment, each animal received an intraperitoneal injection of naltrexone -HCl (10 mg/kg in 1 ml of normal saline) 30 min before sacrifice.
Autoradiographic studies were carried out by using a combination of the methods of Herkenham and Pert (16) , Kuhar and co-workers (17) , and Penney, Young, and co-workers (18) . Animals were sacrificed by decapitation, and brains were rapidly removed and frozen by immersion in isopentane at -55°C for 30 sec. Brains were then mounted on cryostat chucks by using Lipshaw embedding matrix. Coronal sections (24 ,um) were cut at -18°C, thaw-mounted onto gel§To whom reprint requests should be addressed.
3893
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. For peptide determinations, naltrexone-treated and control rats were sacrificed by decapitation, and the brains were rapidly removed. Dissections were performed immediately on ice, using the atlases of Paxinos and Watson (19) as previously described (12) . The following five regions were used: (i) neocortex, (ii) nucleus accumbens, (iii) hypothalamus, (iv) striatum, and (v) periaqueductal gray; the tissue from a single animal was used for each determination. Tissue was homogenized in 0.1 M acetic acid at 4°C, using a hand-held ground-glass micro tissue grinder; the following volumes were used: (i) neocortex, 8 ml; (ii) nucleus accumbens, 8 ml; (iii) hypothalamus, 4 ml; (iv) striatum, 8 ml; (v) periaqueductal gray, 2 ml (21). Samples were analyzed for methionineenkephalin content by using a standard radioimmunoassay (RIA) kit (Immunonuclear, Stillwater, MN). All samples were incubated in duplicate with 125I-labeled methionine-enkephalin for 18 hr at 0C. Radioactivities of samples were determined by using a gamma counter. The experiment was replicated in four independent sets of animals. Results are reported as mean ± SEM. Statistical significance was assessed by the t test for independent measures (P < 0.05).
RESULTS
The neuroanatomical localization of opiate receptor upregulation was visualized by using light microscopy autoradiography. Corresponding brain sections from various brain regions of rats from all drug treatment groups were incubated with radiolabeled ligand on the same day, in the same solutions, and exposed to the same sheet of LKB film to enable comparison of all brain sections. Autoradiograms of coronal sections through the telencephalic region are shown in Fig.  1 receptors were observed, surrounded by areas of diffusely organized receptors. Dense labeling was also observed along the subcallosal streak. This topographical organization of receptors is similar to that previously reported (16, 22, 23) . In the case of brain exposed to chronic naltrexone (Fig. lb) , receptor density in the striatal patches was markedly increased relative to that of control brain (Fig. la) , whereas the diffusely labeled receptors of surrounding areas remained essentially unchanged. Additional structures apparent in this autoradiogram and that exhibited pronounced receptor density changes were the nucleus accumbens and lateral septal nuclei (Fig. 1) , areas known to contain dopamine as a neurotransmitter. The neocortex of control animals labeled under these binding conditions (Fig. la) revealed opiate-receptor-rich layers, as previously reported (16, 24) . Whereas layers I and III showed significant increases in receptor density after chronic naltrexone treatment (Fig. lb) , layers II, IV, V, and VI remained unchanged.
Nuclei of the thalamus exhibited high densities of dihydro[3H]morphine binding (Fig. 2) . Long-term naltrexone administration (Fig. 2b) resulted in an increase in binding to the posterior thalamic nucleus but produced no significant change in binding to the lateral or medial ventroposterior thalamic nuclei relative to control brains (Fig. 2a) Proc. NatL. Acad ScL USA 81 (1984) 3895 region of the hippocampus (Fig. 2) very dense labeling of ,u receptors was seen to overlie the molecular layers; diffuse labeling was observed in the surrounding areas. Autoradiography (Fig. 2b) revealed antagonist-induced increases in opiate receptor density closely opposed to the pyramidal cells within the molecular layers of the hippocampus (e.g., mossy fiber tract and CA3 area) but not in the dentate gyrus; surrounding areas were not affected. This pattern is similar to that observed for the striatum, in that only densely organized IL receptors were observed to undergo upregulation. In the midbrain area the periaqueductal gray, a major locus implicated in the regulation of pain perception, is moderately labeled by dihydro[3H]morphine (Fig. 3a) . Antagonistinduced density increases were observed in this structure (Fig. 3b) . Also seen in this set of autoradiograms is the superior colliculus, in which opiate receptors overlie the molecular layers (Fig. 3a) . A pronounced antagonist-induced increase was observed in the superficial gray layer (Fig. 3b) of this structure. Table 1 summarizes the quantification of opiate receptor density changes following chronic naltrexone treatment in these brain regions. Largest increases (>90%) were observed in layer I of the neocortex, the nucleus accumbens, Brain sections were labeled in vitro with 5 nM dihydro[3H]morphine and opposed to tritium-sensitive film for 12 weeks before development. Nonspecific binding in every case was less than 8 ± 2% of total binding. Thus the minimum specific binding was 92 ± 2% of total binding. Values as reported represent specific binding and have been obtained by subtracting (i) background film density and (ii) nonspecific binding from total binding. Readings were taken from at least three sections from each structure per rat and averaged. Averages of values obtained from more than one rat are expressed as mean ± SD (n = 2). The reproducibility of optical density readings for a particular brain region varied less than 10% among animals of the same treatment group. Findings are reported as percent change from control levels ± SD. the amygdala, the ventral tegmental area, the ventromedial hypothalamus, the substantia nigra compacta, and the central gray area. Most of these structures are areas particularly rich in dopamine cell bodies. Moderate increases (45-89%)
were observed in layer III of the neocortex, patches of the striatum, the lateral septum, the posterior thalamic nucleus, the superior colliculus, the medial habenular nuclei, and the molecular layer of the hippocampus. Small increases in receptor density (21-33%) were noted in the dorsal thalamic nucleus and other areas of the hippocampus. No significant changes in density were found in areas surrounding the striatal patches, the medial septum, the lateral habenular nuclei, the ventral thalamic nuclei, and the substantia nigra reticulata. Opiate receptor binding to the rat brainstem at the level of the locus ceruleus revealed dense labeling in the parabrachial nuclei and the locus ceruleus as previously reported (16, 25) . Chronic naltrexone treatment produced significant increases in density in the parabrachial nuclei (+39%) but no significant change in the locus ceruleus, which contains almost exclusively norepinephrine cell bodies (Table 1) .
In separate control experiments, injections of naltrexone HCl (10 mg/kg) 30 min before sacrifice resulted in no significant changes in dihydro[3H]morphine binding relative to nontreated controls as visualized by light microscopy autoradiography (data not shown). Brain slices were incubated at 37TC for 30 min prior to addition of radiolabeled ligand to facilitate removal of endogenous ligand from opiate receptors. Under these conditions opiate receptor number is not affected by acute administration of an opiate antagonist (12) . This finding indicates that the observed pattern of opiate receptor upregulation is not merely a result of dissociation of endogenous ligand.
To examine correlated patterns of peptide regulation, methionine-enkephalin content in brain regions of naltrexonetreated and control animals was measured by radioimmunoassay. The distribution of methionine-enkephalin throughout the brain after long-term exposure to naltrexone is summarized in Table 2 . Two dopamine-rich structures, the striatum and nucleus accumbens, showed significant increases in methionine-enkephalin content after chronic naltrexone treatment (+94% and +45%, respectively; t test, P < 0.05). Moderate increases were detected in the periaqueductal gray and hypothalamic areas. Neocortex showed no significant changes in methionine-enkephalin levels (-15%) after chronic naltrexone treatment.
DISCUSSION
In the present study, light microscopy autoradiography was used to visualize neuroanatomical patterns of brain opiate receptor upregulation in response to chronic naltrexone administration. Pronounced increases in opiate receptor density were observed in nucleus accumbens, the amygdala, striatum, specific nuclei of the thalamus and hypothalamus, layers I and III of the neocortex, substantia nigra compacta, midbrain periaqueductal gray region, and the parabrachial nuclei of the brainstem. The observed increases are most likely to be in A or 8 receptors or both; high-affinity dihydro[3H]morphine sites have been identified with these subtypes (26) . This interpretation is consistent with the finding that increases in receptor density were noted in the striatal patch areas, which are presumed to contain A receptors, but not in the diffusely labeled surrounding area, which is presumed to contain 8 receptors (27) . Increases in methionineenkephalin content were found in striatum, nucleus accumbens, periaqueductal gray, and hypothalamic areas of chronic naltrexone-treated rats relative to control rat brains.
This study demonstrates the usefulness of light microscopy autoradiography as a general method for correlating the distribution of and changes in opiate receptors after drug manipulation. We have shown that specific brain regions vary system, consisting of the nucleus accumbens, the lateral septal nucleus, various nuclei of the hypothalamus, and the amygdala. These areas are known to contain dopamine as a neurotransmitter. There is considerable evidence supporting the notion of dopaminergic-enkephalinergic anatomical and functional interactions (11, (28) (29) (30) . A second important system is the periaqueductal gray matter, thought to play a role in nociception and analgesia (31, 32) . A third includes several of the major structures that receive input from afferent sensory pathways, such as the superficial layers of the superior colliculus, the molecular layers of the hippocampus, layers I and III of neocortex, and the parabrachial nuclei. All of these structures are particularly rich in opiate receptors relative to other areas (25) . These findings are congruent with suggestions that opiates may function as neuromodulators in the central nervous system. When the system is challenged, as by chronic opiate antagonist treatment, specific enkephalinergic pathways (i.e., limbic, pain, sensory pathways) respond by synthesizing or unmasking new receptors. It is also possible that enkephalin levels increase first and that the receptor changes are of a compensatory nature. Changes in levels of /-endorphin have also been reported (33) .
In a preliminary study, this laboratory (12) had reported regional differences in opiate receptor increases in response to chronic naltrexone treatment. In that study [3H]etorphine binding to brain homogenate showed similar increases in the nucleus accumbens, neocortex, hypothalamus, and striatum. However, no significant changes were noted in the central gray or dorsal hippocampal region. In contrast, the autoradiographic techniques used in the present experiment revealed large increases in receptor density in these areas. One possible important factor in these different findings is that the regional binding assays were performed with [3H]etorphine (a nonspecific opiate ligand), while autoradiography was carried out with dihydro[3H]mnorphine (a , agonist).
In summary, light microscopy autoradiography has been used to visualize neuroanatomical patterns of brain opiate receptor upregulation in response to chronic naltrexone administration. Parallel changes in methionine-enkephalin content in these brain regions were also observed. Thus, opioid receptors and peptides appear to be subject to regulatory mechanisms similar to those that modulate other neurotransmitters and their receptors. An understanding of the cellular mechanisms subserving antagonist-induced opiate receptor upregulation may be of use in the therapy of opiate dependence and of neurological and psychiatric disorders involving enkephalinergic mechanisms.
